Akebia Therapeutics Drops Trial Plans for Anemia Treatment After FDA Meeting

Dow Jones

Oct 29, 2025

By Kelly Cloonan

Akebia Therapeutics will not start a proposed trial for its anemia treatment after meeting with the Food and Drug Administration.

The biopharmaceutical company said Tuesday it believes regulatory alignment for the trial would require a significantly larger number of patients than proposed, requiring more time and cost to complete, based on feedback from the FDA.

The proposed trial aimed to study the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease not on dialysis. The treatment is already approved for such patients who have been receiving dialysis for at least three months.

As a result of the FDA's feedback, the company does not plan to initiate the trial or pursue a broad label for its Vafseo anemia treatment in patients not on dialysis.

While the company is disappointed in the outcome of the meeting was encouraged by its discussion with the FDA on smaller subgroups of chronic kidney disease patients, Chief Executive John Butler said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 28, 2025 17:11 ET (21:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579906689"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579906689\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579906689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579906689","market":"nz","top_or_hot":-1,"title":"Akebia Therapeutics Drops Trial Plans for Anemia Treatment After FDA Meeting","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> will not start a proposed trial for its anemia treatment after meeting with the Food and Drug Administration. \n</p>\n<p>\n  The biopharmaceutical company said Tuesday it believes regulatory alignment for the trial would require a significantly larger number of patients than proposed, requiring more time and cost to complete, based on feedback from the FDA. \n</p>\n<p>\n  The proposed trial aimed to study the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease not on dialysis. The treatment is already approved for such patients who have been receiving dialysis for at least three months. \n</p>\n<p>\n  As a result of the FDA's feedback, the company does not plan to initiate the trial or pursue a broad label for its Vafseo anemia treatment in patients not on dialysis. \n</p>\n<p>\n  While the company is disappointed in the outcome of the meeting was encouraged by its discussion with the FDA on smaller subgroups of chronic kidney disease patients, Chief Executive John Butler said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 17:11 ET (21:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics Drops Trial Plans for Anemia Treatment After FDA Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics Drops Trial Plans for Anemia Treatment After FDA Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-29 05:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> will not start a proposed trial for its anemia treatment after meeting with the Food and Drug Administration. \n</p>\n<p>\n  The biopharmaceutical company said Tuesday it believes regulatory alignment for the trial would require a significantly larger number of patients than proposed, requiring more time and cost to complete, based on feedback from the FDA. \n</p>\n<p>\n  The proposed trial aimed to study the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease not on dialysis. The treatment is already approved for such patients who have been receiving dialysis for at least three months. \n</p>\n<p>\n  As a result of the FDA's feedback, the company does not plan to initiate the trial or pursue a broad label for its Vafseo anemia treatment in patients not on dialysis. \n</p>\n<p>\n  While the company is disappointed in the outcome of the meeting was encouraged by its discussion with the FDA on smaller subgroups of chronic kidney disease patients, Chief Executive John Butler said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 17:11 ET (21:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579906689","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579906689","pubTimestamp":1761685860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Akebia Therapeutics will not start a proposed trial for its anemia treatment after meeting with the Food and Drug Administration.The biopharmaceutical company said Tuesday it believes regulatory alignment for the trial would require a significantly larger number of patients than proposed, requiring more time and cost to complete, based on feedback from the FDA.The proposed trial aimed to study the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease not on dialysis. The treatment is already approved for such patients who have been receiving dialysis for at least three months.As a result of the FDA's feedback, the company does not plan to initiate the trial or pursue a broad label for its Vafseo anemia treatment in patients not on dialysis.While the company is disappointed in the outcome of the meeting was encouraged by its discussion with the FDA on smaller subgroups of chronic kidney disease patients, Chief Executive John Butler said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AKBA":"Akebia Therapeutics, Inc."},"translate_title":"FDA会议后Akebia Therapeutics放弃贫血治疗试验计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Akebia Therapeutics will not start a proposed trial for its anemia treatment after meeting with the Food and Drug Administration. \n\n\n  The biopharmaceutical company said Tuesday it believes regulatory alignment for the trial would require a significantly larger number of patients than proposed, requiring more time and cost to complete, based on feedback from the FDA. \n\n\n  The proposed trial aimed to study the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease not on dialysis. The treatment is already approved for such patients who have been receiving dialysis for at least three months. \n\n\n  As a result of the FDA's feedback, the company does not plan to initiate the trial or pursue a broad label for its Vafseo anemia treatment in patients not on dialysis. \n\n\n  While the company is disappointed in the outcome of the meeting was encouraged by its discussion with the FDA on smaller subgroups of chronic kidney disease patients, Chief Executive John Butler said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2025 17:11 ET (21:11 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}